Aminotadalafil

Aminotadalafil, formally (6R,12aR)-2-amino-6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione (CAS 385769-84-6), is a synthetic structural analog of tadalafil, the selective cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) inhibitor marketed as Cialis for the treatment of erectile dysfunction, pulmonary arterial hypertension, and benign prostatic hyperplasia. The single structural modification that distinguishes aminotadalafil from the parent drug is the replacement of the N-methyl substituent on the 2-position of the piperazinedione (diketopiperazine) ring with a primary amino group (NH2), a change that alters hydrogen-bonding capacity, basicity, and physicochemical properties while preserving the core beta-carboline-fused diketopiperazine scaffold responsible for PDE5 active-site recognition. Aminotadalafil retains inhibitory activity at PDE5 and exhibits greater than 100 percent cross-reactivity with anti-tadalafil polyclonal antibodies, confirming close structural and immunochemical homology with the parent compound [1]. The compound has not undergone formal preclinical toxicology, human pharmacokinetic characterization, or clinical efficacy evaluation in any regulatory jurisdiction, and it is not approved for human use by any national medicines authority. Its principal significance in the biomedical literature arises from its repeated identification as an undeclared adulterant in dietary supplements, herbal products, and electronic cigarette liquids marketed for sexual enhancement, where it poses uncharacterized risks to consumers who are unaware of its presence and who may be concurrently taking nitrate-containing medications or other agents that interact with the cGMP-nitric oxide signaling pathway [2, 3, 4, 5].

The analytical chemistry literature on aminotadalafil is substantial. The compound has been identified and structurally characterized by proton and carbon-13 nuclear magnetic resonance spectroscopy, electrospray ionization mass spectrometry, Fourier transform infrared spectroscopy, and ultraviolet spectrophotometry in dietary supplement matrices across multiple continents, including reports from Latin America, Asia, Europe, and North America [2, 6, 7]. Validated high-performance liquid chromatography with diode array detection (HPLC-DAD) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods permit simultaneous identification and quantification of aminotadalafil alongside other PDE5 inhibitor analogs (hydroxythiohomosildenafil, thiosildenafil, dimethylsildenafil, thiodimethylsildenafil) in complex supplement matrices [3, 8]. A dimeric interaction product of aminotadalafil has also been isolated from adulterated health food products, suggesting that the compound undergoes degradation or condensation reactions under storage conditions encountered in supplement manufacture [9].

The pharmacological characterization of aminotadalafil is limited. No peer-reviewed study has reported a direct IC50 determination for aminotadalafil against recombinant human PDE5, and no selectivity panel across the eleven mammalian phosphodiesterase families has been published. The compound's activity is inferred from its structural homology to tadalafil (IC50 approximately 1.8 to 5.0 nanomolar against PDE5) and from the immunochemical cross-reactivity data. Structure-activity relationship studies of the broader tadalafil analog series indicate that modifications at the 2-position of the diketopiperazine ring modulate PDE5 affinity, and that the (6R,12aR) stereochemistry derived from L-tryptophan is essential for potent inhibition [10, 11]. Aminotadalafil preserves this stereochemistry. No human pharmacokinetic, dose-response, or safety data exist; toxicological risk assessment must therefore rely on extrapolation from tadalafil and on the general pharmacology of the PDE5 inhibitor class. This monograph reviews the chemistry, structural pharmacology, inferred pharmacokinetics, regulatory history, detection methodology, sourcing considerations, and comparative assessment of aminotadalafil against five alternative PDE5 inhibitor analogs encountered in the adulterated supplement landscape.